CAS 1192171-69-9

4-Chloro-5-(4-((2,6-dichlorophenyl)sulfonyl)piperazin-1-yl)benzofuran-2-carboxylic acid

CAS: 1192171-69-9

Formel: C₁₉H₁₅Cl₃N₂O₅S

Reinheit: 98%

Farbe und Form: Solid

Molekulargewicht: 489.7568

Ref: IN-DA01V2UY

4-Chloro-5-(4-((2,6-Dichlorophenyl)Sulfonyl)Piperazin-1-Yl)Benzofuran-2-Carboxylic Acid

CAS: 1192171-69-9

4-Chloro-5-(4-((2,6-Dichlorophenyl)Sulfonyl)Piperazin-1-Yl)Benzofuran-2-Carboxylic Acid

Formel: C₁₉H₁₅Cl₃N₂O₅S

Reinheit: 98%

Molekulargewicht: 489.76

Ref: 54-OR1023053

Vonafexor

CAS: 1192171-69-9

Vonafexor

Formel: C₁₉H₁₅Cl₃N₂O₅S

Reinheit: ≥98%

Molekulargewicht: 489.76

Ref: 54-BUP06737

Vonafexor

CAS: 1192171-69-9

Vonafexor (EYP001) is a farnesoid X receptor (FXR, NR1H4) agonist, with anti-HBV effects

Formel: C₁₉H₁₅Cl₃N₂O₅S

Reinheit: 98.74%

Farbe und Form: White Solid

Molekulargewicht: 489.76

Ref: TM-T8471

Vonafexor

CAS: 1192171-69-9

4-Chloro-5-(4-((2,6-dichlorophenyl)sulfonyl)piperazin-1-yl)benzofuran-2-carboxylic acid

Formel: C₁₉H₁₅Cl₃N₂O₅S

Reinheit: 98%

Molekulargewicht: 489.76

Ref: IN-DG01218047

Vonafexor

CAS: 1192171-69-9

Vonafexor is an inhibitor that is used in combination with other drugs for the treatment of non-alcoholic steatohepatitis. Vonafexor is a potent inhibitor of fatty acid synthase, which may be responsible for the reduction of liver fat and inflammation in patients with non-alcoholic steatohepatitis. It has also been shown to inhibit lipoprotein lipase and block sterol uptake, leading to decreased cholesterol synthesis. Vonafexor has not been associated with any adverse events and has no known drug interactions.

Formel: C₁₉H₁₅Cl₃N₂O₅S

Reinheit: Min. 95%

Molekulargewicht: 489.8 g/mol

Ref: 3D-SXB17169